Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7878977 | 0.86 | PRKCA (0.36) | PRKCA | |
| SCHEMBL6882137 | 0.85 | ALDH1A1 (0.36) | PRKCA | |
| SCHEMBL6882068 | 0.80 | MGAM (0.33) | — | |
| SCHEMBL6886654 | 0.80 | ALDH1A1 (0.31) | — | |
| SCHEMBL24960593 | 0.79 | PRKCA (0.43) | PRKCAMMP8 | |
| SCHEMBL6887994 | 0.78 | PRKCA (0.40) | PRKCAMMP8 | |
| SCHEMBL1507276 | 0.76 | PRKCA (0.37) | PRKCA | |
| SCHEMBL638234 | 0.73 | PRKCA (0.35) | PRKCA | |
| SCHEMBL1639936 | 0.73 | PRKCA (0.44) | PRKCAMMP8 | |
| SCHEMBL1396438 | 0.73 | PRKCA (0.44) | PRKCAMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ROHM AND HAAS COMPANY | 2004-12-16 | — | — | US | disclosed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002072559-A1 | PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | MULVIHILL MARK JOSEPH (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055082-A2 | INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ABCB1, ABCB11, ABCG2 | PRKCA 4855/4885MMP8 288/4885 |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | DDT, CYP4X1, CYP1B1 | PRKCA 1954/4885MMP8 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.